Reviewing VistaGen Therapeutics Inc. (VTGN)’s and Celgene Corporation (NASDAQ:CELG)’s results

VistaGen Therapeutics Inc. (NASDAQ:VTGN) and Celgene Corporation (NASDAQ:CELG), both competing one another are Biotechnology companies. We will contrast their profitability, institutional ownership, analyst recommendations, risk, dividends, earnings and valuation.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
VistaGen Therapeutics Inc. N/A 0.00 20.02M -0.94 0.00
Celgene Corporation 15.28B 4.01 4.05B 5.57 12.34

We can see in table 1 the earnings per share (EPS), gross revenue and valuation of VistaGen Therapeutics Inc. and Celgene Corporation.


Table 2 hightlights the net margins, return on assets and return on equity of the two companies.

Net Margins Return on Equity Return on Assets
VistaGen Therapeutics Inc. 0.00% -328.5% -187.7%
Celgene Corporation 26.51% 56.8% 8.7%

Risk and Volatility

VistaGen Therapeutics Inc.’s volatility measures that it’s 206.00% more volatile than S&P 500 due to its -1.06 beta. Celgene Corporation’s 47.00% more volatile than S&P 500 which is a result of the 1.47 beta.


The current Quick Ratio of VistaGen Therapeutics Inc. is 6.5 while its Current Ratio is 6.5. Meanwhile, Celgene Corporation has a Current Ratio of 2.1 while its Quick Ratio is 2. VistaGen Therapeutics Inc. is better positioned to pay off its short-term and long-term debts than Celgene Corporation.

Analyst Ratings

The following table given below contains the ratings and recommendations for VistaGen Therapeutics Inc. and Celgene Corporation.

Sell Ratings Hold Ratings Buy Ratings Rating Score
VistaGen Therapeutics Inc. 0 0 0 0.00
Celgene Corporation 0 6 2 2.25

Meanwhile, Celgene Corporation’s average target price is $88.17, while its potential upside is 0.80%.

Institutional & Insider Ownership

Roughly 11.6% of VistaGen Therapeutics Inc. shares are owned by institutional investors while 76.3% of Celgene Corporation are owned by institutional investors. 2.47% are VistaGen Therapeutics Inc.’s share owned by insiders. On the other hand, insiders owned about 0.33% of Celgene Corporation’s shares.


In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
VistaGen Therapeutics Inc. -1.67% -14.49% 28.26% 24.65% -12.81% 58.97%
Celgene Corporation -4.9% -8.98% -22.96% -12.32% -33.15% -34.19%

For the past year VistaGen Therapeutics Inc. had bullish trend while Celgene Corporation had bearish trend.


On 9 of the 11 factors Celgene Corporation beats VistaGen Therapeutics Inc.

VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing medicines for depression and other central nervous system (CNS) disorders. The company's lead product candidate is AV-101, which is in Phase II development stage, an adjunctive treatment used for major depressive disorder. It also focuses on potential commercial applications of its human pluripotent stem cell (hPSC) technology platform to discover, rescue, develop, and commercialize new chemical entities (NCEs) for CNS and other diseases; and regenerative medicine involving hPSC-derived blood, cartilage, heart, and liver cells. In addition, the company develops CardioSafe 3D, an in vitro cardiac bioassay system for predicting human heart toxicity of small molecule NCEs. VistaGen Therapeutics, Inc. has licensing, sublicensing, and collaboration agreements with BlueRock Therapeutics, LP; U.S. National Institutes of Health; Cato Research Ltd.; and University Health Network. The company was founded in 1998 and is headquartered in South San Francisco, California.

Celgene Corporation discovers, develops, and commercializes therapies to treat cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma, myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis, psoriasis, and ankylosing spondylitis; and ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers. The companyÂ’s products also include VIDAZA, a pyrimidine nucleoside analog for intermediate-2 and high-risk MDS, chronic myelomonocytic leukemia, and acute myeloid leukemia (AML); THALOMID to treat patients with multiple myeloma and erythema nodosum leprosum; and RITALIN and FOCALIN XR products. Its clinical stage products comprise OTEZLA for use in treating various immune-inflammatory diseases; luspatercept for beta-thalassemia and MDS; CC-486 to treat MDS, AML, and solid tumors; AG-881 for glioma with IDH mutations; LSD1 inhibitor to treat non-hodgkin lymphoma and solid tumors; CC-122 and CC-220 to treat hematological and solid tumor cancers, and inflammation and immunology diseases; and durvalumab, an anti-PDL-1 antibody, for multiple hematological cancers. The company has a strategic collaboration with BeiGene, Ltd. and Nimbus Therapeutics. It also has collaborative agreements with Acceleron Pharma, Inc.; Agios Pharmaceuticals, Inc.; Sutro Biopharma, Inc.; bluebird bio, Inc.; FORMA Therapeutics Holdings, LLC; OncoMed Pharmaceuticals, Inc.; NantBioScience, Inc.; AstraZeneca PLC; Lycera Corp.; Juno Therapeutics, Inc.; Nurix Inc.; Jounce Therapeutics, Inc.; and Dragonfly Therapeutics, Inc. Celgene Corporation was founded in 1980 and is headquartered in Summit, New Jersey.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.